Release Summary

Biodesix (US, Colorado) and Bioyong (China, Beijing) are entering into a USD $38M agreement to develop and commercialize a version of the VeriStrat liquid biopsy test for NSCLC (lung cancer) in China.

Biodesix, Inc.